Artelo Biosciences Stock Jumps 45% On Promising Preclinical Antidepressant Data

(RTTNews) - Artelo Biosciences, Inc. (ARTL) soared 44.98 percent to $14.57 after unveiling encouraging preclinical results for its novel drug candidate, ART12.11, at the International Cannabinoid Research Society Symposium. The stock opened sharply higher at $21.56 and traded between $15.00 and $23.52 on the Nasdaq. Volume surged to 6.67 million shares, well above the average of 543,813. Shares had previously closed at $10.05, and the stock's 52-week range now stands at $4.92 to $25.58.

The compound, a cocrystal of cannabidiol and tetramethylpyrazine demonstrated potential to alleviate stress-induced depressive symptoms and cognitive impairments in animal models.